黄芪多糖注射液对冠心病患者血清心肌酶谱、SOD、MDA表达水平的影响

摘要

Objective To observe the effect ofastragalus polysaccharide injection on serum myocardial enzymes,superoxide dismutase (SOD),and malondialdehyde (MDA) in patients with coronary heart disease (CHD).Methods 70 patients with CHD were randomly divided into a control group and an observation group,35 cases for each group.Both groups were given routine treatment;in addition,the observation group were treated with astragalus polysaccharide injection.Both groups were treated for 14 days.The levels of serum myocardial enzymes,SOD,and MDA in the two groups were compared before and after treatment.Results There were no statistical differences in the levels of serum LDH,CK,and CK-MB between the two groups before treatment (P＞ 0.05).After treatment,the levels of serum LDH,CK and CK-MB in the two groups were significantly lower than those before treatment (P ＜ 0.05) and the decrease was more significant in the observation group than in the control group (P ＜ 0.05).There were no statistical differences in the levels of serum SOD and MDA between the two groups before treatment (P ＞ 0.05).After treatment,the serum SOD levels increased slightly and MDA level decreased slightly in the control group (P ＞ 0.05);in the observation group,the serum SOD level was significantly higher and MDA level was significantly lower than those before treatment and those in the control group (P ＜ 0.05).Conclusion Astragalus polysaccharide injection can reduce serum MDA level and increase SOD level in patients with CHD.Therefore,the balance between oxidation and antioxidation can be regulated and the myocardial enzymes can be improved,enhancing the therapeutic effects.%目的 观察黄芪多糖注射液对冠心病患者血清心肌酶谱、超氧化物歧化酶(SOD)、丙二醛(MDA)表达水平的影响.方法 将70例冠心病患者按对照研究方式分为对照组和观察组,每组35例.两组患者均给予抗血小板、调节血脂等常规治疗,观察组在此基础上给予黄芪多糖注射液治疗,均持续治疗14 d.观察比较治疗前后两组患者血清心肌酶谱、SOD、MDA表达水平.结果 治疗前,两组患者血清LDH、CK、CK-MB水平差异均无统计学意义(均P＞0.05).治疗后,两组患者血清LDH、CK、CK-MB水平较治疗前均明显降低(均P＜0.05),且观察组较对照组LDH、CK、CK-MB水平明显降低(均P＜ 0.05).治疗前,两组患者血清SOD、MDA水平差异均无统计学意义(均P＞0.05).治疗后,对照组患者血清SOD较治疗前略有升高(P＞0.05),MDA水平较治疗前略有降低(P＞0.05),观察组患者血清SOD较治疗前明显升高(P＜0.05),MDA较治疗前明显降低(P＜0.05);且观察组较对照组SOD水平明显升高(P＜0.05),MDA水平明显降低(P＜0.05).结论 黄芪多糖注射液可降低冠心病患者血清MDA水平,升高SOD水平,从而调节机体氧化与抗氧化平衡,并明显改善患者心肌酶谱,增强治疗效果.